Archives of Alzheimer's & Parkinson's Disease

Alzheimer's and Parkinson's diseases are two of the most prominent and complex progressive neurological disorders that have a profound global impact [1,2]. These diseases affect millions of individuals worldwide, causing significant morbidity and placing a substantial burden on healthcare systems and society [3,6]. Despite considerable advancements in understanding these disorders over the years, developing effective treatments remains a complex and multifaceted challenge [7,8].

National studies of Parkinson’s disease (PD) provide critical data for healthcare planning, yet methodological limitations continue to undermine their utility. This review examines recent epidemiological work, including the Greek nationwide analysis, to highlight three priority areas for refinement: diagnostic accuracy, survival methodology, and recognition of disease heterogeneity.

Alzheimer's disease (AD) and Parkinson's disease (PD) constitute a leading cause of disability and death worldwide. Millions of people are currently afflicted with AD and PD with numbers expected to double by mid-century, if effective disease-modifying treatments do not become available. There is no cure for AD or PD. Current Food and Drug Administration (FDA)-approved treatments are symptomatic which do not halt the progression of the disease and are associated with adversities.

India can be regarded as an agricultural country where 46% of its land is utilized for farming [1]. Since ancient times, plants have been utilized for their edible properties and for medicinal and therapeutic purposes. The ancient medicinal science Ayurveda strongly recommends the use of natural ingredients in the form of food to remain healthy and also to cure various ailments. 

Alzheimer’s disease and related dementias (ADRD) are widely studied conditions, yet the populations represented in dementia research do not always reflect the diversity of individuals who age with these disorders. Transgender and gender-diverse populations remain largely absent from many epidemiological datasets and longitudinal cohort studies that inform current models of cognitive aging.